Lapatinib: new opportunities for management of breast cancer.

about

A Validated RP-HPLC Method for the Estimation of Lapatinib in Tablet Dosage form using Gemcitabine Hydrochloride as an Internal Standard.Novel Adamantanyl-Based Thiadiazolyl Pyrazoles Targeting EGFR in Triple-Negative Breast Cancer.PATRI, a Genomics Data Integration Tool for Biomarker Discovery

P2860

Q43120670-C19166EE-F328-42F3-A69B-1DBB98E19CAB Q55654447-0E63B037-87CC-43AD-88BA-B492C6AAAC42 Q58883545-F23AE02D-079E-47DB-88B0-DDE5A9D7F75E

P2860

Lapatinib: new opportunities for management of breast cancer.

Item

http://www.wikidata.org/entity/Q37355729

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

2010年學術文章

@zh

2010年學術文章

@zh-hant

name

Lapatinib: new opportunities for management of breast cancer.

@en

Lapatinib: new opportunities for management of breast cancer.

@nl

type

Item

label

Lapatinib: new opportunities for management of breast cancer.

@en

Lapatinib: new opportunities for management of breast cancer.

@nl

prefLabel

Lapatinib: new opportunities for management of breast cancer.

@en

Lapatinib: new opportunities for management of breast cancer.

@nl

P1476

Lapatinib: new opportunities for management of breast cancer.

@en

P2093

Joyce Slingerland

http://www.w3.org/2001/XMLSchema#string

Julia Liao

http://www.w3.org/2001/XMLSchema#string

Mark Pegram

http://www.w3.org/2001/XMLSchema#string

Michelle Gallas

http://www.w3.org/2001/XMLSchema#string

P2860

Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Lapatinib plus capecitabine for HER2-positive advanced breast cancer.

Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4.

Untangling the ErbB signalling network

Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas

A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells

Serum HER-2/neu and relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer

Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers

P304

79-91

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/BCTT.S5929

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2010-11-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24367169

http://www.w3.org/2001/XMLSchema#string

P932

3846530

http://www.w3.org/2001/XMLSchema#string

Lapatinib: new opportunities for management of breast cancer.

about

P2860

P2860

Lapatinib: new opportunities for management of breast cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P698

P932